publication date: Apr. 13, 2018

Clinical Roundup NCI study revises molecular classification for most common type of lymphoma

In a new study, researchers identified genetic subtypes of diffuse large B-cell lymphoma that could help explain why some patients with the disease respond to treatment and others don’t.

The study, led by researchers in the Center for Cancer Research at the National Cancer Institute, part of the National Institutes of Health, with additional authors from several institutions around the world, was published in The New England Journal of Medicine.

Researchers still don’t have a full understanding of why some lymphomas of this type respond to treatment and others do not. The standard treatment for the disease is a combination of chemotherapy drugs plus rituximab, a drug known as a monoclonal antibody.

Several years ago, researchers defined two major subgroups of DLBCL that arise from different cells of origin and that have different patterns of gene activity. They found that patients with activated B-cell-like DLBCL have about a 40 percent average survival rate, while those with germinal center B-cell-like DLBCL have about a 75 percent average survival rate. But even in the GCB subgroup, many patients experience disease relapse after treatment.

The investigators performed a multi-platform analysis of genomic alterations and gene expression on tumor samples from 574 patients with DLBCL. This analysis … Continue reading NCI study revises molecular classification for most common type of lymphoma

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2018 The Cancer Letter Inc.